慢性乙型肝炎患者HBV前C区G1896A、核心启动子1762/1764变异与乙型肝炎自然史、血清HBsAg定量及疾病程度的相关性

肝脏 ›› 2017, Vol. 22 ›› Issue (11): 1013-1016.

慢性乙型肝炎患者HBV前C区G1896A、核心启动子1762/1764变异与乙型肝炎自然史、血清HBsAg定量及疾病程度的相关性

胡晨波,严荣妹,金宏慧,丁晓红,李仲平,潘云鹤

201399 上海市浦东新区南华医院肝病科

出版日期:2017-11-15 发布日期:2020-06-15
通讯作者: 胡晨波,Email:hcb197836@163.com
基金资助:
上海市浦东新区卫生和计划生育委员会科技发展专项基金资助(PWRq2014-60)

Online:2017-11-15 Published:2020-06-15

摘要/Abstract

摘要： 目的研究HBV前C区G1896A、核心启动子1762/1764变异与HBV自然史、血清HBsAg水平间的相关性及对疾病严重程度的影响。方法分别各选取40例HBV野生株、前C区G1896A或核心启动子1762/1764变异以及两者联合变异的慢性乙型肝炎感染者为研究对象。采用PCR反向点杂交技术检测HBV前C区G1896A位点、核心启动子1762/1764变异及HBV基因分型。同时检测HBsAg定量、HBeAg、HBV DNA定量、肝脏生化指标等。结果 (1)HBV前C区G1896A、核心启动子1762/1764变异患者的年龄、ALT高于野生株感染者(P<0.001),Alb低于野生株感染者(P<0.001)。(2)HBV自然史免疫耐受期以野生株感染为主(P<0.001),免疫清除期、低(非)复制期野生株及PC G1896A或/和BCP1762/1764变异株差异无统计学意义(P>0.05),再活动期以PC G1896A或/和BCP1762/1764变异株为主(P<0.001)。(3)PC G1896A或/和BCP1762/1764变异株的HBsAg水平(lgIu/mL)、HBeAg阳性率较野生株组降低(P<0.001),基因C型、HBV DNA水平(≥6 lg拷贝/mL)较野生株组差异无统计学意义(P>0.05)。(4)HBV PC G1896A或/和BCP1762/1764变异中肝硬化患者多于野生株(P<0.05)。结论慢性HBV感染者前C区G1896A、核心启动子1762/1764变异与乙型肝炎自然史、HBsAg水平、HBeAg的状态及疾病严重程度相关。

胡晨波,严荣妹,金宏慧,丁晓红,李仲平,潘云鹤. 慢性乙型肝炎患者HBV前C区G1896A、核心启动子1762/1764变异与乙型肝炎自然史、血清HBsAg定量及疾病程度的相关性[J]. 肝脏, 2017, 22(11): 1013-1016.

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).中国肝脏病杂志(电子版),2015,7:1-18.
[2] Semenov AV,Vlasova IA,Ostankova IuV,et al.Quantitative determination of HBsAg in blood sera and hepatitis B virus covalently closed circular DNA in liver tissue as markers of chronic viral hepatitis B activity.Zh Mikrobiol Epidemiol Immunobiol,2014,(1):55-61.
[3] Tu WH,Lv Y,Zhang YM,et al. Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by Simpleprobe.World J Gastroenterol,2015,21: 6639-6648.
[4] Martinot-Peignoux M, Lapalus M, Asselah T, et al. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int,2014, 34 Suppl 1: 97-107.
[5] Chuaypen N,Sriprapun M, Praianantathavorn K,et al.Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol,2017,89:130-138.
[6] Pivert A,Servant-Delmas A,Lunel-Fabiani F, et al.Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus.J Med Virol,2015,87:529-535.
[7] Liu MH,Chen QY,Harrison TJ,et al.The correlation between serum HBsAg levelsand viral loads depends upon wild-type andmutated HBV sequences rather than the HBeAg/anti-HBe status.J Med Virol,2015,87:1351-1360.
[8] Pollicino T,Amaddeo G,Restuccia A,et al.Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology, 2012,56:434-443.
[9] Choi JW,Ahn SH,Park JY,et al.Hepatitis B e antigen-negative mutations in the prefore and core premoter regions in Korean patients.J Med Virol,2009,81:594-601.
[10] Scaglioni PP, Melegari M, Wands JP. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology,1997,233: 374-381.
[11] Kramvis A,Arakawa K,Yu MC,et al. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J Med Virol,2008,80:27-46.
[12] Du H, Li T, Zhang HY,et al.Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection.Liver Int, 2007,27:240-246.
[13] Park YM, Jang JW, Yoo SH, et al. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat,2014,21: 171-177.
[14] Xie Y, Liu S, Zhao Y, et al. Precore/Core Region Mutations in Hepatitis B Virus DNA Predict Postoperative Survival in Hepatocellular Carcinoma. PLoS One,2015, 10:e0133393.
[15] Wu JF, Ni YH, Chen HL, et al. The impact of hepatitis B virus precore/core gene carboxyl terminal mutations on viral biosynthesis and the host immune response. J Infect Dis,2014,209: 1374-1381.
[16] Chu CM, Lin CC, Chen YC, et al.Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.Br J Cancer,2012,107:2010-2015.
[17] Zhong YW, Di FL, Liu C,et al.Hepatitis B virus basal core Promoter/precore mutants and association with liver cirrhosis inchildren with chronic hepatitis B virusinfection.Clin Microbiol Infect,2016,22:379.e1-8.